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Background: The purposes of this study were to explore whether the maternal-fetal outcomes differed among
various types of hyperglycemia during pregnancy and whether the values of glycemic screening in the middle
phase of pregnancy could predict maternal-fetal outcomes.
Methods: A retrospective study was conducted to study the incidence of maternal-fetal outcomes in 383 singleton
pregnant women with diabetes or gestational diabetes admitted to our hospital from November 2007 to March 2013.
Patients were divided into three groups: DM (Type 1 and Type 2 diabetes mellitus) group, mGDM (mild gestational
diabetes mellitus) group and sGDM (severe gestational diabetes mellitus) group. Maternal basic characteristics,
results of oral glucose tolerance test (OGTT), antenatal random glycemia and maternal-fetal outcomes were collected.
Binary logistic regression was used to estimate the association of blood glucose with the maternal-fetal outcomes.
Predictive accuracy was assessed by calculating the areas under the receiver operating characteristic curves.
Results: The maternal basic characteristics, maternal complications and neonatal complications did not differ
significantly between DM group and sGDM group, except neonatal intensive care units admission (NICU). Incidences
of preterm, NICU and preeclampsia were significantly lower in the mGDM group than in the DM and sGDM groups
(P < 0.05). After adjusted by confounding factors, the value of OGTT 0 h could predict pregnancy induced hypertension
(PIH) (OR = 1.24, 95% CI [1.04 to 1.46], P = 0.015), preterm birth (OR = 1.23, 95% CI [1.03 to 1.47], P = 0.025) and stillbirth
(OR = 1.55, 95% CI [1.14 to 2.10], P = 0.005); antenatal random glycemia could predict preterm birth (OR = 1.19, 95% CI
[1.08 to 1.31], P < 0.001) and stillbirth (OR = 1.41, 95% CI [1.17 to 1.71], P < 0.001).
Conclusions: Pregnant women in the mGDM group have better outcomes than those in the DM and sGDM groups.
The values of OGTT in the middle phase of pregnancy and antenatal random glycemia could predict PIH, preterm birth
or stillbirth to some extent.Background
In recent years, the incidence of gestational diabetes melli-
tus (GDM) has increased in China. According to the results
of a prospective study enrolling more than 10,000 pregnant
women in 18 cities, the incidence ranges from 4.3% to
5.1% in China [1,2]. Lots of studies have shown that
maternal hyperglycemia during pregnancy is associated
with increased risk of specific maternal-fetal complications,
including pregnancy induced hypertension (PIH), pre-
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[3-5]. In the long term, for the mothers, there is an
increased risk for developing Type 2 diabetes mellitus
(T2DM) after pregnancy [2,6]; for the offspring, studies
have provided substantial evidences that intrauterine
exposure to maternal hyperglycemia has lifelong effects,
including increased risk of obesity [7,8], T2DM [9,10],
metabolic [11-14] and cardiovascular disease [15,16]
and even cancer [17]. These hyperglycemia-related short
or long term dysfunctions are not only confined to
women with Type 1 diabetes mellitus (T1DM) or T2DM
diagnosed before gestation, but are also observed in
women with GDM. Fortunately, studies have shown
that appropriate managements such as dietary, moderate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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could reduce the risk of complications and improve
maternal and neonatal outcomes [18-22]. Therefore, the
diagnosis and management of GDM are important in that
it poses risks to both the mothers and their babies [6,23].
GDM has been defined as any degree of glucose intoler-
ance with onset or first recognition during pregnancy [24].
If the fasting glucose ≥ 7 mmol/L or HbA1c ≥6.5% or oral
glucose tolerance test (OGTT) 2 h ≥ 11.1 mmol/L, one
should be considered to be pre-diabetes [24]. The manage-
ment of this kind of severe gestational diabetes mellitus
(sGDM) might be more demanding than mild gestational
diabetes mellitus (mGDM) [22]. McCance DR suggested
treating and following up sGDM as pre-existing diabetes
[25]. However, until recently, it is not clear that whether
differences exist in maternal-fetal outcomes among
various types of hyperglycemia and whether the values
of glycemic screening in the middle phase of pregnancy
could predict specific maternal-fetal outcomes. So the
aims of our study were to explore that 1) whether the
maternal-neonatal outcomes differed among various types
of hyperglycemia during pregnancy; 2) whether the values
of OGTT and antenatal random glycemia could predict
specific maternal or neonatal complications.
Methods
Study subjects
This was a retrospective study of 383 singleton pregnant
women with pre-existing diabetes mellitus (DM) or GDM
and their offspring who delivered in Tongji Hospital affili-
ated to Huazhong University of Science and Technology
from November 2007 to March 2013. The Ethics Commit-
tee of Tongji Hospital approved the study (in accordance
with the Helsinki declaration). There were 53 pregnant
women with DM and 330 with GDM. The inclusion
criteria for patients with GDM before November 2011
were as follows [26]: fasting glycemic level ≥ 5.8 mmol/L
for at least twice; two or more glycemic values exceed the
cutoff points of 75 g OGTT (fasting ≥ 5.6 mmol/L,
1 h ≥ 10.3 mmol/L, 2 h ≥ 8.6 mmol/L, 3 h ≥ 6.7 mmol/L).
Others were diagnosed according to the new criteria of
American Diabetes Association published in 2011: any
of the plasma glucose values exceeded the cutoff points
of 75 g OGTT (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L,
2 h ≥ 8.5 mmol/L) [27]. Patients with the following condi-
tions were excluded from the study: patients with DM had
no exact diagnosis and patients with GDM were without
definite outcomes of OGTT.
Groups
Patients with diabetes mellitus diagnosed before gestation
were classified in the DM group (n = 53, 2 are T1DM,
others are T2DM). For the GDM women, classification
was based on values of OGTT. They were divided intotwo groups including severe GDM (sGDM, n = 135, fast-
ing ≥ 7 mmol/L or OGTT 2 h ≥ 11.1 mmol/L) and mild
GDM (mGDM, n = 195, fasting < 7 mmol/L and OGTT
2 h < 11.1 mmol/L).
Statistical analysis
The data were summarized as frequencies or percent-
ages for categorical variables and as means and stand-
ard deviations or medians and interquartile ranges for
continuous variables, depending on the distribution.
Differences between the groups were compared by the
chi-square or Fisher’s exact test for categorical variables
and multiple comparisons in ANOV or Kruskal Wallis
Test for continuous variables. Associations of blood
glucose levels with the maternal and neonatal outcomes
were assessed by binary logistic regression, unadjusted
first, and then adjusted for age, history of spontaneous
abortion, history of stillbirth, family history, living
place, diagnose time of GDM, maternal weight before
delivery and treatment. Predictive accuracy of mater-
nal/neonatal outcomes and blood sugar levels were
assessed by calculating the areas under the receiver op-
erating characteristic (ROC) curves, which were com-
pared according to the method of Hanley and McNeil;
optimal cutoff values were chosen as the point on the
ROC curve, closest to the top left corner. A nominal 2-
sided probability value < 0.05 was considered to indi-
cate statistical significance, and adjustments were made
for multiple comparisons in chi-square test and Kruskal
Wallis Test (Padjust < 0.017). All of the calculations were
performed using the SPSS 12.0 (SPSS Inc. Chicago, IL).
Results
In this study, patients in DM group had a median diabetic
history of about 2 years (1.75-5y). The median diagnosis
time of GDM was 210 days (186-237d) for mGDM and
233 days (197-253d) for sGDM after pregnancy. The
diagnosis time of patients in mGDM group was much
earlier than that in sGDM group (P = 0.001). There was
no significant difference between DM group and sGDM
group in maternal basic characteristics, maternal com-
plications and neonatal complications except neonatal
intensive care units (NICU) admission. When compared
with the DM and sGDM groups, the time of delivery was
much later in mGDM group; values of OGTT 0 h, 1 h,
2 h, antenatal random glycemia, incidence of preterm and
NICU admission were significantly lower in mGDM
group. Significant difference was found in the incidences
of PIH and stillbirth only between mGDM and sGDM
groups. Family history and history of stillbirth were signifi-
cantly less in mGDM group than in DM group (P < 0.05,
Padjust < 0.017). Several maternal and neonatal characteris-
tics were similar across the three groups. These details
were shown in Table 1.
Table 1 Comparison of maternal basic characters, maternal-fetal complications
Characteristic DM mGDM sGDM
(n = 53) (n = 198) (n = 132)
Age (year) 30.32 ± 4.62 30.83 ± 4 31 ± 4.76
Family history (%) 26.4 11.6a 18.2
History of spontaneous abortion (%) 15.1 14.6 15.2
History of stillbirth (%) 9.4 1.5a 4.5
Chronic hypertension (%) 5.7 1 0.8
OGTT 0 h (mmol/L)† 8.5 (7.03-10.42) 5.28 (4.88-5.62)ab 7.53 (6.46-9.16)
OGTT 1 h (mmol/L)‡ 15.17 ± 1.63 10.64 ± 1.57ab 13.35 ± 2.87
OGTT 2 h (mmol/L)§ 15.33 ± 3.13 9.12 ± 1.06ab 14.13 ± 3.66
Maternal weight before delivery (kg)¶ 75 (65.23-89.63) 74 (66.62-80) 73.75 (63–83.5)
Neonatal weight (kg)|| 3.49 ± 0.75 3.41 ± 0.46 3.46 ± 0.60
Cesarean rate (%) 88.7 92.9 85.6
Time of delivery (day) 264 (250.5-270) 268 (263–274)ab 263.5 (252.25-272)
Antenatal random glycemia (mmol/L)†† 7.67 (5.5-10.22) 5.61 (4.75-6.7)ab 7.31 (5.17-9.63)
Ketoacidosis (%) 0 0 1.5
PIH (%) 18.9 9.1b 27.3
Preeclampsia (%) 15.1 5.6b 16.7
Premature rupture of membranes (%) 17 6.1 8.3
Fetal distress (%) 13.2 4 7.6
Polyhydramnios (%) 7.5 2 2.3
Oligohydramnios (%) 1.9 4 6.1
Hyperthyroidism (%) 1.9 0.5 0
Hypothyroidism (%) 0 2 0
Vaginitis (%) 1.9 1 0
NICU (%)‡‡ 40b 10.9ab 21.5a
Neonatal jaundice (%)‡‡ 20 10.9 10
Neonatal deformity (%)‡‡ 2.2 1.1 0
Stillbirth (%)‡‡ 6.7 0.5b 6.2
Preterm birth (%)§§ 36.5 12.8ab 31.7
Neonatal hypoglycemia (%)‡‡ 0 0 0.8
Neonatal asphyxia (%)‡‡ 0 5.5 6.2
Neonatal infection (%)‡‡ 0 1.1 0
†The values are based on 9 women in group DM, 154 women in group mGDM and 88 women in group sGDM.
‡The values are based on 5 women in group DM, 171 women in group mGDM and 52 women in group sGDM.
§The values are based on 7 women in group DM, 174 women in group mGDM and 77 women in group sGDM.
¶The values are based on 46 women in group DM, 176 women in group mGDM and 106 women in group sGDM.
||The values are based on 31 women in group DM, 164 women in group mGDM and 94 women in group sGDM.
††The values are based on 50 women in group DM, 183 women in group mGDM and 128 women in group sGDM.
‡‡The values are based on 45 women in group DM, 183 women in group mGDM and 130 women in group sGDM.
§§The values are based on 52 women in group DM, 196 women in group mGDM and 126 women in group sGDM.
acompare with group DM, there is a significant difference (P < 0.05, Padjust < 0.017 for multiple comparisons in chi-square test and Kruskal Wallis Test).
bcompare with group sGDM, there is a significant difference (P < 0.05, Padjust < 0.017 for multiple comparisons in chi-square test and Kruskal Wallis Test).
OGTT: oral glucose tolerance test; PIH: pregnancy induced hypertension; NICU: neonatal intensive care unit.
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during pregnancy, 5.7% only used dietary and 56.6% added
insulin. The proportions were respectively 29.3%, 58.6%,
12.1% in mGDM group and 32.6%, 22.7%, 44.7% in sGDM
group. Patients adding insulin were significantly fewer inmGDM group than in DM group (P < 0.001) and sGDM
group (P < 0.001). However, in the aspect of treatment,
there was no significant difference between DM and sGDM
groups (P = 0.143). The average blood glucose levels for the
patients with various treatments were in Table 2.
Table 2 Glycemic levels in different kinds of treatments
No treatment Diet only Adding insulin
OGTT 0 h (mmol/L)† 6.71 ± 2.34 5.68 ± 1.45 7.09 ± 2.52
OGTT 1 h (mmol/L)† 10.93 ± 2.13 10.82 ± 1.84 12.76 ± 2.70
OGTT 2 h (mmol/L)† 10.53 ± 2.92 9.70 ± 2.04 12.80 ± 4.30
Antenatal random glycemia (mmol/L)‡ 7.83 ± 3.77 6.08 ± 1.86 7.38 ± 3.42
†The values were based on the data in mGDM and sGDM groups.
‡The values were based on the data in DM, mGDM and sGDM groups.
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and several maternal-fetal complications including PIH
(OR = 0.57, 95%CI [0.33, 0.99], P = 0.047), polyhydramnios
(OR = 0.25, 95%CI [0.07, 0.88], P = 0.031) and stillbirth
(OR = 0.22, 95%CI [0.06, 0.74], P = 0.015). Maternal weight
before delivery was closely related to PIH (OR = 1.02, 95%
CI [1.00, 1.04], P = 0.032) and preeclampsia (OR = 1.04,
95%CI [1.01, 1.06], P = 0.003). The values of OGTT were
not associated with maternal or neonatal complications
except PIH, preterm birth, or stillbirth. PIH and preterm
birth were closely related to the values of OGTT 0 h.
Stillbirth was closely related to the values of OGTT 0 h
and 2 h. Of all the neonatal complications, antenatal
random glycemia level was mainly related to stillbirth
and preterm birth. Table 3 showed the results of logistic
regression analysis for blood glucose levels and maternal-




OR 1.06 1.06 1.07
95% CI 0.98-1.15 0.96-1.17 0.98-1.17
P Value 0.116 0.214 0.151
OGTT 0 h‡
OR 1.21 1.24 1.23
95% CI 1.06-1.38 1.04-1.46 1.06-1.43
P Value 0.004 0.015 0.006
OGTT 1 h‡
OR 1.11 1.21 1.05
95% CI 0.95-1.30 0.98-1.51 0.86-1.29
P Value 0.195 0.08 0.628
OGTT 2 h‡
OR 1.05 1.08 1.07
95% CI 0.95-1.16 0.93-1.26 0.95-1.20
P Value 0.35 0.32 0.255
†The values were based on the data in DM, mGDM and sGDM groups. The confoun
history of spontaneous abortion, history of stillbirth, living place, maternal weight b
‡The values were based on the data in mGDM and sGDM groups. The confounders
spontaneous abortion, history of stillbirth, living place, maternal weight before deliv
OGTT: oral glucose tolerance test; PIH: pregnancy induced hypertension.ROC analysis showed that the value of OGTT 0 h could
predict PIH in this population (P < 0.001). Both the values
of OGTT 0 h and antenatal random glycemia could pre-
dict preterm birth (P < 0.001). For stillbirth, the values of
OGTT 0 h, OGTT 2 h and antenatal random glycemia
were predictors (P = 0.013, P = 0.049, P < 0.001). Details
were shown in Figure 1.
Discussion
From the results, we found that the maternal basic charac-
ters, maternal complications and neonatal complications
except NICU were similar in sGDM group and DM
group. This suggests that GDM patients with fasting
glucose ≥ 7 mmol/L or OGTT 2 h ≥ 11.1 mmol/L might
have diabetes before pregnancy. The prognoses of the
two groups were worse than that of the mGDM group,
especially the sGDM group. This might result fromith the maternal-fetal outcomes
mpsia Preterm birth Stillbirth
Adjusted Unadjusted Adjusted Unadjusted Adjusted
1.10 1.17 1.19 1.48 1.41
0.98-1.23 1.07-1.27 1.08-1.31 1.27-1.72 1.17-1.71
0.105 <0.001 <0.001 <0.001 <0.001
1.22 1.26 1.23 1.64 1.55
0.99-1.49 1.09-1.46 1.03-1.47 1.25-2.15 1.14-2.10
0.052 0.002 0.025 <0.001 0.005
1.14 1.06 1.10 1.77 0
0.87-1.49 0.91-1.24 0.91-1.35 1.16-2.70 0
0.352 0.423 0.323 0.008 0.948
1.08 1.09 1.07 1.21 1.49
0.91-1.27 0.99-1.20 0.95-1.22 1.03-1.42 1.04-2.14
0.384 0.052 0.274 0.022 0.031
ders for which OR values were adjusted comprised of age, family history,
efore delivery and treatment.
for which OR values were adjusted comprised of age, family history, history of
ery, diagnose time of GDM and treatment.
Figure 1 ROC analysis for hyperglycemia in middle and late pregnancy and maternal-fetal outcomes. (A) ROC analysis for OGTT 0 h and
PIH (P < 0.001, areas under the ROC curve: 0.697; sensitivity: 77.3% and specificity: 62.6% for a cutoff of 5.76 mmol/L). (B) ROC analysis for OGTT
0 h and preterm birth (P < 0.001, areas under the ROC curve: 0.671; sensitivity: 63% and specificity: 68.5% for a cutoff of 5.96 mmol/L). (C) ROC
analysis for OGTT 0 h and stillbirth (P = 0.013, areas under the ROC curve: 0.826; sensitivity: 60% and specificity: 96.9% for a cutoff of 11.78 mmol/L). (D)
ROC analysis for OGTT 2 h and stillbirth (P = 0.049, areas under the ROC curve: 0.787; sensitivity: 75% and specificity: 74.4% for a cutoff of 11.7 mmol/L).
(E) ROC analysis for antenatal random glycemia and preterm birth (P < 0.001, areas under the ROC curve: 0.653; sensitivity: 69.1% and specificity: 59.9%
for a cutoff of 6.30 mmol/L). (F) ROC analysis for antenatal random glycemia and stillbirth (P < 0.001, areas under the ROC curve: 0.901; sensitivity: 90%
and specificity: 89.9% for a cutoff of 10 mmol/L).
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ketoacidosis appearing. Most patients in sGDM group
were diagnosed in the 33rd week of pregnancy who
might have suffered glycemic abnormality for a long
period without treatment and have developed some
maternal complications in an early phase, let alone the
influence of combination with poor treatments. In this
study, for all patients together, the average antenatal
random glycemia of patients adding insulin was 7.38 ±
3.42 mmol/L which did not satisfy the control standards
and was much higher than that of patients only using diet.
This indicates that the added dose of insulin might be not
enough to control the blood sugar. Many Chinese women
are reluctant to use medicine during pregnancy because
of the misconceptions that the medicines used mightharm their babies. Even if some patients in DM group
had received insulin therapy before pregnancy, they
refused insulin injection after they became pregnant.
The bad relationship between doctors and patients in
China might also have contributed to the inadequate
usage of insulin. Some pregnant women didn’t regularly
come to do prenatal examinations or monitor blood
glucose at home, even doubted what doctors said.
Moreover, compliance to the usage of insulin in sGDM
group was worse than those patients with diabetes for
many years for that they had never come into contact
with insulin injection before, so their treatment efficiency
was even worse than that in DM group. Some random
control trials have demonstrated that for gestational
diabetes, a comprehensive management of dietary and
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outcomes [28,29]. Therefore, we should emphasize health
education and help those women change the misunder-
standing of medicine use in pregnancy. Moreover, we
should pay more attention to the patients with sGDM
such as adding frequency of antenatal care, closely
monitoring in clinical work and the most important
one is early diagnosis.
In addition, more patients in DM and sGDM groups
required insulin supplement. The average blood glucose
levels of OGTT of those adding insulin could be used as
references for clinicians, with the aim of managing the
glycemia in an earlier stage and avoiding severe maternal
and neonatal complications.
One study has suggested that, in GDM, increased
severity of insulin resistance and related features of the
“metabolic syndrome” are precursors to the development
of preeclampsia [30]. Maternal obesity could aggravate
the complications [31]. In our study, maternal weight
before delivery was closely positively related to PIH and
preeclampsia in accordance with the studies above.
What’s more, through the ROC analysis, the value of
OGTT 0 h could predict the occurrences of PIH and
preterm birth; the values of OGTT 0 h and OGTT 2 h
could both predict the occurrence of stillbirth. Therefore,
we should pay more emphasis on those with OGTT 0 h ≥
5.76 mmol/L or OGTT 2 h ≥ 11.7 mmol/L, at the same
time actively control the blood glucose under the target
(fasting < 5.3 mmol/L, postprandial 2 h < 6.7 mmol/L) and
rigorously monitor blood pressure, maternal weight, fetal
heart rate and fetal movement so as to reduce severe
maternal and neonatal complications.
Glycemic level in the late pregnancy is directly related
to the baby’s safety. Even in women with a mild degree
of GDM, proper management of both mother and fetus
could reduce the number of unexplained stillbirths [32].
Our study also showed that women with poor perinatal
blood sugar easily suffered stillbirth and premature birth.
Premature birth might lead to neonatal long term com-
plications which might bring economic burden to both
family and society. Therefore, active control of antenatal
blood glucose level is an effective method to prevent
neonatal complications.
However, there were some limitations in our research. It
was a single center study and the sample size was small,
so the sensitivity and specificity of results were not so
satisfactory. With the standardization of the diagnosis
and treatment of GDM, we will get more accurate and
particular data in China.
Conclusions
Pregnant women in the mGDM group have better out-
comes than those in the DM and sGDM groups. The
values of OGTT and antenatal random glycemia couldpredict PIH, stillbirth or preterm birth to some extent.
Active control of antenatal blood sugar is beneficial to
reduce neonatal complications. What’s more, for the
pregnant women with OGTT 0 h ≥ 7 mmol/L or OGTT
2 h ≥ 11.1 mmol/L, we should actively use enough insulin,
perform health education and improve maternal compli-
ance so as to avoid severe maternal-fetal complications.
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